Role of PLGA Variability in Controlled Drug Release from Dexamethasone Intravitreal Implants

被引:2
|
作者
Costello, Mark A. [1 ]
Liu, Joseph [1 ]
Kuehster, Louise [2 ]
Wang, Yan [3 ]
Qin, Bin [3 ]
Xu, Xiaoming [4 ]
Li, Qi [3 ]
Smith, William C. [4 ]
Lynd, Nathaniel A. [2 ,5 ]
Zhang, Feng [1 ]
机构
[1] Univ Texas Austin, Coll Pharm, Dept Mol Pharmaceut & Drug Delivery, Austin, TX 78712 USA
[2] Univ Texas Austin, McKetta Dept Chem Engn, Austin, TX 78712 USA
[3] US FDA, Ctr Drug Evaluat & Res, Off Gener Drugs, Off Res & Stand, Silver Spring, MD 20993 USA
[4] US FDA, Off Testing & Res, Off Pharmaceut Qual, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA
[5] Univ Texas Austin, Texas Mat Inst, Austin, TX 78712 USA
关键词
PLGA; implant; Ozurdex; hot-melt extrusion; blockiness; acid number; MONOMER SEQUENCE; PHARMACOKINETICS;
D O I
10.1021/acs.molpharmaceut.3c00742
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Long-acting injectable formulations based on poly-(lactide-co-glycolide) (PLGA) have been commercialized for over 30 years in at least 20 FDA-approved products. These formulations offer several advantages, including reduced dosing frequency, improved patient compliance, and maintenance of therapeutic levels of drug. Despite extensive studies, the inherent complexity of the PLGA copolymer still poses significant challenges associated with the development of generic formulations having drug release profiles equivalent to those of the reference listed drugs. In addition, small changes to PLGA physicochemical properties or the drug product manufacturing process can have a major impact on the drug release profile of these long-acting formulations. This work seeks to better understand how variability in the physicochemical properties of similar PLGAs affects drug release from PLGA solid implants using Ozurdex (dexamethasone intravitreal implant) as the model system. Four 50:50, acid-terminated PLGAs of similar molecular weights were used to prepare four dexamethasone intravitreal implants structurally equivalent to Ozurdex. The PLGAs were extensively characterized by using a variety of analytical techniques prior to implant manufacture using a continuous, hot-melt extrusion process. In vitro release testing of the four structurally equivalent implants was performed in both normal saline and phosphate-buffered saline (PBS), yielding drastically different results between the two methods. In normal saline, no differences in the release profiles were observed. In PBS, the drug release profiles were sensitive to small changes in the residual monomer content, carboxylic acid end group content, and blockiness of the polymers. This finding further underscores the need for a physiologically relevant in vitro release testing method as part of a robust quality control strategy for PLGA-based solid implant formulations.
引用
收藏
页码:6330 / 6344
页数:15
相关论文
共 50 条
  • [1] PLGA implants for controlled drug release: Impact of the diameter
    Bassand, C.
    Freitag, J.
    Benabed, L.
    Verin, J.
    Siepmann, F.
    Siepmann, J.
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2022, 177 : 50 - 60
  • [2] Enhancing drug release from PEG-PLGA implants: The role of Hydrophilic Dexamethasone Phosphate in modulating release kinetics and degradation behavior
    Lehner, Eric
    Trutschel, Marie-Luise
    Menzel, Matthias
    Jacobs, Jonas
    Kunert, Julian
    Scheffler, Jonas
    Binder, Wolfgang H.
    Schmelzer, Christian E. H.
    Plontke, Stefan K.
    Liebau, Arne
    Maeder, Karsten
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2025, 209
  • [3] In vitro and In vivo Sustained Release of Dexamethasone from Intravitreal Implants
    Tully, Janet
    Yang, Mari
    Williams, Stuart
    Das, Sanjib
    Verhoeven, Rozemarijn S.
    Robeson, RiLee
    Schiffman, Rhett M.
    Yerxa, Benjamin R.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)
  • [4] Optimising the controlled release of dexamethasone from a new generation of PLGA-based microspheres intended for intravitreal administration
    Rodriguez Villanueva, Javier
    Bravo-Osuna, Irene
    Herrero-Vanrell, Rocio
    Molina Martinez, Irene Teresa
    Guzman Navarro, Manuel
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2016, 92 : 287 - 297
  • [5] Drug release mechanisms of high-drug-load, melt-extruded dexamethasone intravitreal implants
    Costello, Mark A.
    Liu, Joseph
    Chen, Beibei
    Wang, Yan
    Qin, Bin
    Xu, Xiaoming
    Li, Qi
    Lynd, Nathaniel A.
    Zhang, Feng
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2023, 187 : 46 - 56
  • [6] Influence of PLGA End Groups on the Release Profile of Dexamethasone from Ocular Implants
    Saraf, Isha
    Kushwah, Varun
    Alva, Carolina
    Koutsamanis, Ioannis
    Rattenberger, Johannes
    Schroettner, Hartmuth
    Mayrhofer, Claudia
    Modhave, Dattatray
    Braun, Michael
    Werner, Bernd
    Zangger, Klaus
    Paudel, Amrit
    MOLECULAR PHARMACEUTICS, 2023, : 1307 - 1322
  • [7] STUDY OF RELEASE KINETICS OF DEXAMETHASONE FROM BIODEGRADABLE PLGA IN-SITU IMPLANTS
    Dewan, Irin
    Islam, S. M. Ashraful
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2011, 2 (11): : 3039 - 3045
  • [8] Intracochlear PLGA based implants for dexamethasone release: Challenges and solutions
    Lehner, E.
    Guendel, D.
    Liebau, A.
    Plontke, S.
    Maeder, K.
    INTERNATIONAL JOURNAL OF PHARMACEUTICS-X, 2019, 1
  • [9] Precision Size and Shape Extended Release Intravitreal Dexamethasone Implants
    Das, Sanjib Kiumar
    Williams, Stuart
    Tully, Janet
    Verhoeven, Rozemarijin S.
    Yang, Mari
    Navratil, Tomas
    Schiffman, Rhett
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2016, 57 (12)
  • [10] PLGA implants for controlled dexamethasone delivery: Impact of the polymer chemistry
    Wachowiak, S.
    Danede, F.
    Willart, J. F.
    Siepmann, F.
    Siepmann, J.
    Hamoudi, M.
    JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 2023, 86